Flex Pharma, Inc. (NASDAQ:FLKS) enjoyed a 34.23% run-up in share price since hitting record low of $0.26. The stock managed 5.12% rise and now stands at $0.35 as of 3/13/2019. At a recent session, the prices were hovering between $0.3301 and $0.37. This company shares are 5614.29% off its target price of $20 and the current market capitalization stands at $6.27M. The recent change has given its price a 2.15% lead over SMA 50 and -96.11% deficit over its 52-week high. The stock witnessed 9.51% gains, -16.88% declines and -24.96% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found FLKS’s volatility during a week at 10.77% and during a month it has been found around 9.55%.

Flex Pharma, Inc. (FLKS) Top Holders

Institutional investors currently hold around $1 million or 11.7% in FLKS stock. Look at its top three institutional owners: Renaissance Technologies Llc owns $341 thousand in Flex Pharma, Inc., which represents roughly 5.44% of the company’s market cap and approximately 34.1% of the institutional ownership. Similar statistics are true for the second largest owner, Ameriprise Financial Inc, which owns 270,187 shares of the stock are valued at $90 thousand. The third largest holder is Susquehanna International Group, Llp, which currently holds $57 thousand worth of this stock and that ownership represents nearly 0.91% of its market capitalization.

Flex Pharma, Inc. 13F Filings

At the end of December reporting period, 9 institutional holders increased their position in Flex Pharma, Inc. (NASDAQ:FLKS) by some 650,763 shares, 13 decreased positions by 833,889 and 10 held positions by 638,648. That puts total institutional holdings at 2,123,300 shares, according to SEC filings. The stock grabbed 5 new institutional investments totaling 292,321 shares while 6 institutional investors sold out their entire positions totaling 450,906 shares.

Flex Pharma, Inc. (FLKS) on March 6, 2019 announced its financial results for the three months and fiscal year ended December 31, 2018.

Total revenue for the three months ended December 31, 2018 was approximately $163,000. Total revenue for the year ended December 31, 2018 was approximately $0.8 million, including approximately approximately $11,000 of other revenue.

Cost of product revenue for the three months ended December 31, 2018 was approximately $75,000. There were no inventory write-offs during the three months ended December 31, 2018. Cost of product for the twelve months ended December 31, 2018 was approximately $431,000 and included inventory write offs of approximately $85,000.

Research and development expense for the three months ended December 31, 2018 was $0.2 million and $11.9 million for the year ended December 31, 2018. Research and development expense for these time periods primarily included costs associated with the Company’s clinical operations and wind-down of FLX-787 Phase 2 clinical studies, personnel costs (including salaries, termination-related costs, retention-related costs and stock-based compensation costs) and external consultant costs.